Published in Cancer Weekly, April 24th, 2006
"PPAR gamma exert diverse effects on cancer cells. Recent studies showed that rosiglitazone, a synthetic ligand for PPAR gamma, inhibits cell growth. However, the exact mechanisms underlying this effect are still being explored, and the relevance of these findings to lung cancer remains unclear," wrote S.W. Han and colleagues, Emory University.
"Here," they continued, "we report that rosiglitazone reduced the phosphorylation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.